SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Patricia who wrote (27511)1/20/1999 9:15:00 PM
From: notyet  Read Replies (2) | Respond to of 32384
 
I did it! First time.

Forget sex or Monday-night-football, for that matter. This is it.
I started a new thread on ATLC. Subject 25098 This really hypes me up.
Who the hell created this internet baby.The Nobel prize for them, now!
Currently I am sifting thru the evidence and I will post findings
later.
Feel free to join me.
Everybody is welcome.
I have this gut feeling that antisense will change the world.
There's no pun whatsoever. My gut's got brains.
I don't need pundits . I have my gut.
Am I bugging you? I don't mean to bug you.
Antisense just makes me go hmmh.
And Pat are you really a girl? Just asking.



To: Patricia who wrote (27511)1/20/1999 9:41:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
Kiplinger inaugural chat session just ended. Author admitted that LGND was his favorite and had only good things to say. He mentioned major sector consolidation and when asked about the breast cancer prevention trial between Tamoxifen and Evista, he said to keep an eye on Targretin. Ligand was the most talked about company.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News